Literature DB >> 24393247

New therapeutics in primary biliary cirrhosis: will there ever be light?

Pietro Invernizzi1, M Eric Gershwin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24393247     DOI： 10.1111/liv.12354

Source DB:  PubMed          Journal:  Liver Int        ISSN： 1478-3223            Impact factor:   5.828


× No keyword cloud information.
  4 in total

1.  Unmet challenges in immune-mediated hepatobiliary diseases.

Authors:  Ulrich Beuers; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 2.  The coexistence of Sjögren's syndrome and primary biliary cirrhosis: a comprehensive review.

Authors:  Ying Sun; Weici Zhang; Baosen Li; Zhengsheng Zou; Carlo Selmi; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

3.  Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA.

Authors:  Atsushi Tanaka; Junko Hirohara; Yasuni Nakanuma; Hirohito Tsubouchi; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2014-09-20       Impact factor: 7.527

Review 4.  New developments in the treatment of primary biliary cholangitis - role of obeticholic acid.

Authors:  Manan A Jhaveri; Kris V Kowdley
Journal:  Ther Clin Risk Manag       Date:  2017-08-21       Impact factor: 2.423
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.